Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 111

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 111
---
 Phase 1-2 clinical trials (these partnerships could range from non-profit organizations like      
 Carb-X for advancing novel treatment development to co-development with larger Pharma companies); |

| - | Concentrating on indications where antibiotic resistance poses                                                                               
 a significant and immediate clinical challenge, and where Nano-Mupirocin can offer a distinct advantage; - Accelerating regulatory approvals 
 through pathways like Breakthrough Therapy Designation or Priority Review; - Utilizing adaptive regulatory pathways and engaging in early    
 dialogue with regulatory agencies to expedite the development timeline in order to achieve early regulatory milestones; - To further         
 develop and strengthen its IP strategy and submit more patent applications for method of production and methods of use, including Orphan     
 Drug Designation protection for chosen diseases;                                                                                             |

| ● | To                                                                                                                                 
 generate high-impact publications in reputable scientific and medical journals in collaboration with KOLs and leading researchers. |

| ● | If                                                                                                                                     
 the Company successfully conduct clinical trials, we plan to publish pivotal trials data and to present it at major pharmaceutical and 
 medical industry conferences. Positive data can significantly increase valuation and attract acquisition interest.                     |

The Company’s strategy for maximizing long-term value includes:

| ● | Expanding the development program to include a wider range of indications, demonstrating the versatility and broad applicability of Nano-Mupirocin across various infectious diseases. This can significantly enhance the long-term market potential. |

| ● | Developing a comprehensive target market strategy that includes key regions affected by antibiotic resistance. Tailoring market approaches to fit regional healthcare landscapes is expected to maximize adoption and revenue generation. |

| ● | Cultivating long-term relationships and collaborations with key institutions, health organizations, like WHO and NIH, NGOs, and governments, especially in regions with high burdens of antibiotic-resistant infections. These partnerships can facilitate market access, drive adoption, and support public health initiatives. |

<div align='center'>68</div>

With respect to Development of ARB combination therapy, our strategy includes:

| ● | Early Collaborative Ventures: Initiate strategic collaborations with leading oncology-focused pharmaceutical companies early in the development cycle, particularly following promising preclinical results or early-phase clinical trial success. These collaborations could encompass licensing deals, co-development agreements, or joint ventures, aimed at leveraging external expertise and resources to accelerate ARB’s progression through clinical development and regulatory pathways. |

| ● | Target High-Impact Indications: Prioritize cancer indications where the tumor microenvironment (TME) significantly impacts treatment outcomes and where current therapeutic options are limited. Focusing on